TheEdgeResearch
Home / Stocks / MVRBF

Medivir AB (publ) (MVRBF)

OTC Healthcare Biotechnology
$0.82 ▲ +0.00%
Market Cap
$45.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.36
52-Wk Range
0.68-0.9
CEO
Jens Lindberg
Country
SE
Currency
USD

Medivir AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Huddinge, SE. The stock last traded at $0.82, up 0.00% on the session, giving a market capitalisation of $45.8M. On trailing twelve-month figures it carries a trailing P/E of -5.27, a net margin of -2013.7%. Its beta of 0.36 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5.27
Price / Sales
106.22
Price / Book
2.42
EV / EBITDA
-5.60
Gross margin
100.0%
Operating margin
-1981.7%
Net margin
-2013.7%
Return on equity
—
Debt / equity
0.08
Current ratio
4.39
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
10
IPO date
2010-06-22
Headquarters
Huddinge, SE
About Medivir AB (publ)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Comparable companies

Medivir AB (publ) is most often compared with the following Healthcare names:

ACOGFBSTGDMTTFHRPMFIGXTKDEVFMSSTFNEVPFONPPFRLFTD
More research on MVRBF
MVRBF technical analysis MVRBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →